Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Sep 7, 2026
Barinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsGlobeNewsWire · Aug 24, 2026
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate DevelopmentsGlobeNewsWire · Aug 6, 2026Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.28 | -$0.26 | Beat |
| Apr 30, 2026 | -$0.36 | -$0.14 | Beat |
| Mar 13, 2026 | -$0.40 | -$0.27 | Beat |
| Nov 7, 2025 | -$0.45 | -$0.36 | Beat |
| Aug 7, 2025 | -$0.29 | -$0.52 | Miss |
| May 7, 2025 | -$0.34 | -$0.49 | Miss |